[Skip to Content]
[Skip to Content Landing]

Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice

Educational Objective
To understand that early initiation of endovascular reperfusion therapy for patients with presumed acute ischemic stroke resulting from large vessel occlusion may improve clinical outcomes.
1 Credit CME
Key Points

Question  What is the relation between time to treatment and outcome from endovascular-recanalization therapy for acute ischemic stroke (AIS)?

Findings  In this retrospective cohort study of 6756 patients with AIS in a US nationwide clinical registry, earlier onset to treatment was associated with improved outcomes, including, for every 15 minutes faster treatment: higher rates of independent ambulation (absolute increase, 1.14%), functional independence at discharge (absolute increase, 0.91%), and lower mortality/hospice discharge (absolute decrease, −0.77%).

Meaning  Among patients with AIS treated in routine clinical practice, shorter time to endovascular-recanalization therapy was associated with better outcomes.

Abstract

Importance  Randomized clinical trials suggest benefit of endovascular-reperfusion therapy for large vessel occlusion in acute ischemic stroke (AIS) is time dependent, but the extent to which it influences outcome and generalizability to routine clinical practice remains uncertain.

Objective  To characterize the association of speed of treatment with outcome among patients with AIS undergoing endovascular-reperfusion therapy.

Design, Setting, and Participants  Retrospective cohort study using data prospectively collected from January 2015 to December 2016 in the Get With The Guidelines-Stroke nationwide US quality registry, with final follow-up through April 15, 2017. Participants were 6756 patients with anterior circulation large vessel occlusion AIS treated with endovascular-reperfusion therapy with onset-to-puncture time of 8 hours or less.

Exposures  Onset (last-known well time) to arterial puncture, and hospital arrival to arterial puncture (door-to-puncture time).

Main Outcomes and Measures  Substantial reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3), ambulatory status, global disability (modified Rankin Scale [mRS]) and destination at discharge, symptomatic intracranial hemorrhage (sICH), and in-hospital mortality/hospice discharge.

Results  Among 6756 patients, the mean (SD) age was 69.5 (14.8) years, 51.2% (3460/6756) were women, and median pretreatment score on the National Institutes of Health Stroke Scale was 17 (IQR, 12-22). Median onset-to-puncture time was 230 minutes (IQR, 170-305) and median door-to-puncture time was 87 minutes (IQR, 62-116), with substantial reperfusion in 85.9% (5433/6324) of patients. Adverse events were sICH in 6.7% (449/6693) of patients and in-hospital mortality/hospice discharge in 19.6% (1326/6756) of patients. At discharge, 36.9% (2132/5783) ambulated independently and 23.0% (1225/5334) had functional independence (mRS 0-2). In onset-to-puncture adjusted analysis, time-outcome relationships were nonlinear with steeper slopes between 30 to 270 minutes than 271 to 480 minutes. In the 30- to 270-minute time frame, faster onset to puncture in 15-minute increments was associated with higher likelihood of achieving independent ambulation at discharge (absolute increase, 1.14% [95% CI, 0.75%-1.53%]), lower in-hospital mortality/hospice discharge (absolute decrease, −0.77% [95% CI, −1.07% to −0.47%]), and lower risk of sICH (absolute decrease, −0.22% [95% CI, −0.40% to −0.03%]). Faster door-to-puncture times were similarly associated with improved outcomes, including in the 30- to 120-minute window, higher likelihood of achieving discharge to home (absolute increase, 2.13% [95% CI, 0.81%-3.44%]) and lower in-hospital mortality/hospice discharge (absolute decrease, −1.48% [95% CI, −2.60% to −0.36%]) for each 15-minute increment.

Conclusions and Relevance  Among patients with AIS due to large vessel occlusion treated in routine clinical practice, shorter time to endovascular-reperfusion therapy was significantly associated with better outcomes. These findings support efforts to reduce time to hospital and endovascular treatment in patients with stroke.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Reza Jahan, MD, Division of Interventional Neuroradiology, Department of Radiology, 757 Westwood Plaza, Ste 2129, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 (rjahan@mednet.ucla.edu).

Accepted for Publication: June 11, 2019.

Author Contributions: Drs Jahan and Saver had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Jahan and Saver contributed equally to the study.

Concept and design: Jahan, Saver, Fonarow, Xian, Yavagal, Smith.

Acquisition, analysis, or interpretation of data: Jahan, Saver, Schwamm, Fonarow, Liang, Matsouaka, Xian, Holmes, Peterson, Smith.

Drafting of the manuscript: Jahan, Saver.

Critical revision of the manuscript for important intellectual content: Jahan, Schwamm, Fonarow, Liang, Matsouaka, Xian, Holmes, Peterson, Yavagal, Smith.

Statistical analysis: Saver, Liang, Matsouaka, Xian, Holmes.

Obtained funding: Saver, Fonarow.

Administrative, technical, or material support: Saver, Fonarow, Smith.

Supervision: Jahan, Schwamm, Fonarow.

Conflict of Interest Disclosures: Dr Jahan reports being a consultant for Medtronic Neurovascular, Balt USA, BlackSwan Vascular Inc, and Viz.ai outside the submitted work. Dr Saver reports being an employee of the University of California, which has patent rights in retrieval devices for stroke. Dr Saver reports serving as an unpaid site investigator in multicenter trials sponsored by Medtronic, Stryker, Johnson & Johnson, and Boehringer Ingelheim (prevention only), for which the University of California Regents received payments on the basis of clinical trial contracts for the number of patients enrolled; receipt of contracted hourly payments for services as a scientific consultant advising on rigorous trial design and conduct to Medtronic, Stryker, Johnson & Johnson, and Boehringer Ingelheim (prevention only); and contracted stock options for services as a scientific consultant advising on rigorous trial design and conduct to Rapid Medical. Dr Schwamm reports serving as chair of the stroke clinical work group of Get With The Guidelines-Stroke (GWTG-Stroke) and as a stroke system consultant to the Massachusetts Department of Public Health for the Paul Coverdell National Acute Stroke Registry; and receipt of research support from the Patient-Centered Outcome Research Institute, National Institute of Neurological Disorders and Stroke, and Genentech; and serving as a scientific consultant regarding trial design and conduct to Penumbra (data and safety monitoring committee [Separator 3D and MIND trial]), Genentech (steering committee [TIMELESS trial]), and Medtronic (Victory AF, REACT AF and Stroke AF trials). Dr Fonarow reported serving on the GWTG steering committee; receiving grant funding from the Patient-Centered Outcome Research Institute; being an employee of the University of California, which has a patent on an endovascular therapy device; and serving as a consultant for Janssen. Dr Xian reported receipt of grants from Genentech during the conduct of the study and grants from Genentech outside the submitted work. Dr Peterson reported receipt of grants from Genentech and Regeneron; and grants and personal fees from Sanofi, AstraZenica, Amarin, and Amgen outside the submitted work. Dr Yavagal reported receipt of personal fees from Medtronic, Cerenovus/Johnson & Johnson, Rapid Medical, and Neuralanalytics outside the submitted work. Dr Smith reports serving as consultant for Alnylam Pharmaceuticals and Portola Pharmaceuticals; being a member of the GWTG steering committee; and serving on a data and safety monitoring board for Massachusetts General Hospital. No additional disclosures were reported.

Funding/Support: The GWTG-Stroke program is provided by the American Heart Association (AHA)/American Stroke Association. GWTG-Stroke is sponsored, in part, by Medtronic and has been funded in the past through support from Boehringher Ingelheim, Merck, Bristol-Myers Squib/Sanofi Pharmaceutical Partnership, Janssen Pharmaceutical Companies of Johnson & Johnson and the AHA Pharmaceutical Roundtable.

Role of the Funder/Sponsor: The AHA had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: Drs Saver and Peterson, associate editors for JAMA, were not involved in the editorial review of or decision to publish this article.

References
1.
Goyal  M, Menon  BK, van Zwam  WH,  et al; HERMES Collaborators.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.  Lancet. 2016;387(10029):1723-1731. doi:10.1016/S0140-6736(16)00163-XPubMedGoogle ScholarCrossref
2.
Bracard  S, Ducrocq  X, Mas  JL,  et al; THRACE Investigators.  Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.  Lancet Neurol. 2016;15(11):1138-1147. doi:10.1016/S1474-4422(16)30177-6PubMedGoogle ScholarCrossref
3.
Mocco  J, Zaidat  OO, von Kummer  R,  et al; THERAPY Trial Investigators.  Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone.  Stroke. 2016;47(9):2331-2338. doi:10.1161/STROKEAHA.116.013372PubMedGoogle ScholarCrossref
4.
Muir  KW, Ford  GA, Messow  CM,  et al; PISTE Investigators.  Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial.  J Neurol Neurosurg Psychiatry. 2017;88(1):38-44. doi:10.1136/jnnp-2016-314117PubMedGoogle ScholarCrossref
5.
Albers  GW, Marks  MP, Kemp  S,  et al; DEFUSE 3 Investigators.  Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging.  N Engl J Med. 2018;378(8):708-718. doi:10.1056/NEJMoa1713973PubMedGoogle ScholarCrossref
6.
Nogueira  RG, Jadhav  AP, Haussen  DC,  et al; DAWN Trial Investigators.  Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct.  N Engl J Med. 2018;378(1):11-21. doi:10.1056/NEJMoa1706442PubMedGoogle ScholarCrossref
7.
Mueller-Kronast  NH, Zaidat  OO, Froehler  MT,  et al; STRATIS Investigators.  Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke: primary results of the STRATIS registry.  Stroke. 2017;48(10):2760-2768. doi:10.1161/STROKEAHA.117.016456PubMedGoogle ScholarCrossref
8.
Saver  JL, Goyal  M, van der Lugt  A,  et al; HERMES Collaborators.  Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis.  JAMA. 2016;316(12):1279-1288. doi:10.1001/jama.2016.13647PubMedGoogle ScholarCrossref
9.
Sheth  SA, Jahan  R, Gralla  J,  et al; SWIFT-STAR Trialists.  Time to endovascular reperfusion and degree of disability in acute stroke.  Ann Neurol. 2015;78(4):584-593. doi:10.1002/ana.24474PubMedGoogle ScholarCrossref
10.
Zaidat  OO, Castonguay  AC, Nogueira  RG,  et al.  TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry.  J Neurointerv Surg. 2018;10(6):516-524. doi:10.1136/neurintsurg-2017-013328PubMedGoogle ScholarCrossref
11.
Mulder  MJHL, Jansen  IGH, Goldhoorn  RB,  et al; MR CLEAN Registry Investigators.  Time to endovascular treatment and outcome in acute ischemic stroke: MR CLEAN registry results.  Circulation. 2018;138(3):232-240. doi:10.1161/CIRCULATIONAHA.117.032600PubMedGoogle ScholarCrossref
12.
LaBresh  KA, Reeves  MJ, Frankel  MR, Albright  D, Schwamm  LH.  Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get With The Guidelines” program.  Arch Intern Med. 2008;168(4):411-417. doi:10.1001/archinternmed.2007.101PubMedGoogle ScholarCrossref
13.
Schwamm  LH, Fonarow  GC, Reeves  MJ,  et al.  Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack.  Circulation. 2009;119(1):107-115. doi:10.1161/CIRCULATIONAHA.108.783688PubMedGoogle ScholarCrossref
14.
Ormseth  CH, Sheth  KN, Saver  JL, Fonarow  GC, Schwamm  LH.  The American Heart Association’s Get With the Guidelines (GWTG)-Stroke development and impact on stroke care.  Stroke Vasc Neurol. 2017;2(2):94-105. doi:10.1136/svn-2017-000092PubMedGoogle ScholarCrossref
15.
Berkhemer  OA, Fransen  PS, Beumer  D,  et al; MR CLEAN Investigators.  A randomized trial of intraarterial treatment for acute ischemic stroke.  N Engl J Med. 2015;372(1):11-20. doi:10.1056/NEJMoa1411587PubMedGoogle ScholarCrossref
16.
Powers  WJ, Rabinstein  AA, Ackerson  T,  et al; American Heart Association Stroke Council.  2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.  Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158PubMedGoogle ScholarCrossref
17.
Zaidat  OO, Yoo  AJ, Khatri  P,  et al; Cerebral Angiographic Revascularization Grading (CARG) Collaborators; STIR Revascularization Working Group; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force.  Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement.  Stroke. 2013;44(9):2650-2663. doi:10.1161/STROKEAHA.113.001972PubMedGoogle ScholarCrossref
18.
Seaman  SR, White  IR.  Review of inverse probability weighting for dealing with missing data.  Stat Methods Med Res. 2013;22(3):278-295. doi:10.1177/0962280210395740PubMedGoogle ScholarCrossref
19.
Schieb  LJ, Casper  ML, George  MG.  Mapping primary and comprehensive stroke centers by certification organization.  Circ Cardiovasc Qual Outcomes. 2015;8(6)(suppl 3):S193-S194. doi:10.1161/CIRCOUTCOMES.115.002082PubMedGoogle ScholarCrossref
20.
Saver  JL, Fonarow  GC, Smith  EE,  et al.  Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.  JAMA. 2013;309(23):2480-2488. doi:10.1001/jama.2013.6959PubMedGoogle ScholarCrossref
21.
Kim  JT, Fonarow  GC, Smith  EE,  et al.  Treatment with tissue plasminogen activator in the golden hour and the shape of the 4.5-hour time-benefit curve in the national United States Get With The Guidelines-Stroke population.  Circulation. 2017;135(2):128-139. doi:10.1161/CIRCULATIONAHA.116.023336PubMedGoogle ScholarCrossref
22.
Bhatia  R, Hill  MD, Shobha  N,  et al.  Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.  Stroke. 2010;41(10):2254-2258. doi:10.1161/STROKEAHA.110.592535PubMedGoogle ScholarCrossref
23.
American Heart Association; American Stroke Association.  Severity-based stroke triage algorithm for EMS: 2017. http://www.heart.org/idc/groups/ahaecc-public/@wcm/@gwtg/documents/downloadable/ucm_498615.pdf. Accessed July 2, 2018.
24.
Wheeler  HM, Mlynash  M, Inoue  M,  et al The growth rate of early DWI lesions is highly variable and associated with penumbral salvage and clinical outcomes following endovascular reperfusion.  Int J Stroke. 2015;10(5):723-729. doi:10.1111/ijs.12436PubMedGoogle ScholarCrossref
25.
Bang  OY, Saver  JL, Buck  BH,  et al; UCLA Collateral Investigators.  Impact of collateral flow on tissue fate in acute ischaemic stroke.  J Neurol Neurosurg Psychiatry. 2008;79(6):625-629. doi:10.1136/jnnp.2007.132100PubMedGoogle ScholarCrossref
26.
Bristow  MS, Simon  JE, Brown  RA,  et al.  MR perfusion and diffusion in acute ischemic stroke: human gray and white matter have different thresholds for infarction.  J Cereb Blood Flow Metab. 2005;25(10):1280-1287. doi:10.1038/sj.jcbfm.9600135PubMedGoogle ScholarCrossref
27.
Wegener  S, Gottschalk  B, Jovanovic  V,  et al; MRI in Acute Stroke Study Group of the German Competence Network Stroke.  Transient ischemic attacks before ischemic stroke: preconditioning the human brain? a multicenter magnetic resonance imaging study.  Stroke. 2004;35(3):616-621. doi:10.1161/01.STR.0000115767.17923.6APubMedGoogle ScholarCrossref
28.
Rocha  M, Jovin  TG.  Fast versus slow progressors of infarct growth in large vessel occlusion stroke: clinical and research implications.  Stroke. 2017;48(9):2621-2627. doi:10.1161/STROKEAHA.117.017673PubMedGoogle ScholarCrossref
29.
Albers  GW.  Late window paradox.  Stroke. 2018;49(3):768-771. doi:10.1161/STROKEAHA.117.020200PubMedGoogle ScholarCrossref
30.
Hebert  D, Lindsay  MP, McIntyre  A,  et al Canadian stroke best practice recommendations: Stroke rehabilitation practice guidelines, update 2015.  Int J Stroke. 2016;11(4):459-484. doi:10.1177/1747493016643553PubMedGoogle ScholarCrossref
31.
McTaggart  RA, Ansari  SA, Goyal  M,  et al; Standards and Guidelines Committee of the Society of NeuroInterventional Surgery (SNIS).  Initial hospital management of patients with emergent large vessel occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery.  J Neurointerv Surg. 2017;9(3):316-323. doi:10.1136/neurintsurg-2015-011984PubMedGoogle ScholarCrossref
32.
Sacks  D, Black  CM, Cognard  C,  et al; American Society of Neuroradiology; Canadian Interventional Radiology Association; Cardiovascular and Interventional Radiological Society of Europe; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; European Society of Minimally Invasive Neurological Therapy; Society of Vascular and Interventional Neurology.  Multisociety consensus quality improvement guidelines for intraarterial catheter-directed treatment of acute ischemic stroke, from the American Society of Neuroradiology, Canadian Interventional Radiology Association, Cardiovascular and Interventional Radiological Society of Europe, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, European Society of Minimally Invasive Neurological Therapy, and Society of Vascular and Interventional Neurology.  J Vasc Interv Radiol. 2013;24(2):151-163. doi:10.1016/j.jvir.2012.11.028PubMedGoogle ScholarCrossref
33.
Fonarow  GC, Zhao  X, Smith  EE,  et al.  Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.  JAMA. 2014;311(16):1632-1640. doi:10.1001/jama.2014.3203PubMedGoogle ScholarCrossref
34.
Menon  BK, Xu  H, Cox  M,  et al.  Components and trends in door to treatment times for endovascular therapy in Get With the Guidelines-Stroke hospitals.  Circulation. 2019;139(2):169-179. doi:10.1161/CIRCULATIONAHA.118.036701PubMedGoogle ScholarCrossref
35.
Ovbiagele  B, Saver  JL.  Day-90 acute ischemic stroke outcomes can be derived from early functional activity level.  Cerebrovasc Dis. 2010;29(1):50-56. doi:10.1159/000255974PubMedGoogle ScholarCrossref
36.
Zhang  Q, Yang  Y, Saver  JL.  Discharge destination after acute hospitalization strongly predicts three month disability outcome in ischemic stroke.  Restor Neurol Neurosci. 2015;33(5):771-775.PubMedGoogle Scholar
37.
Goyal  M, Jadhav  AP, Bonafe  A,  et al; SWIFT PRIME Investigators.  Analysis of workflow and time to treatment and the effects on outcome in endovascular treatment of acute ischemic stroke: results from the SWIFT PRIME randomized controlled trial.  Radiology. 2016;279(3):888-897. doi:10.1148/radiol.2016160204PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements